Osmosis Investment Management UK Ltd Purchases Shares of 9,635 DexCom, Inc. $DXCM

Osmosis Investment Management UK Ltd purchased a new stake in DexCom, Inc. (NASDAQ:DXCM) in the 2nd quarter, HoldingsChannel reports. The fund purchased 9,635 shares of the medical device company’s stock, valued at approximately $649,000.

Other hedge funds also recently made changes to their positions in the company. Reflection Asset Management acquired a new position in shares of DexCom in the fourth quarter worth approximately $25,000. Ascentis Independent Advisors acquired a new stake in DexCom during the 1st quarter valued at approximately $25,000. MCF Advisors LLC bought a new stake in shares of DexCom in the 4th quarter valued at $32,000. Wellington Grp LLC raised its stake in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after buying an additional 475 shares during the last quarter. Finally, DV Equities LLC bought a new position in DexCom during the fourth quarter worth $36,000. 97.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on DXCM. JPMorgan Chase & Co. upped their price target on shares of DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. Wells Fargo & Company lifted their price objective on DexCom from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. TD Cowen reissued a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating and set a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Finally, Barclays reaffirmed an “underweight” rating and set a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $88.71.

DexCom Trading Down 2.1%

DXCM opened at $89.16 on Wednesday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The company has a market cap of $33.65 billion, a P/E ratio of 35.24, a price-to-earnings-growth ratio of 1.54 and a beta of 1.41. The company has a fifty day moving average price of $78.15 and a two-hundred day moving average price of $71.19.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The business’s revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.48 EPS. Analysts predict that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 4,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the transaction, the director owned 52,852 shares in the company, valued at approximately $3,917,918.76. This represents a 7.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This trade represents a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 73,035 shares of company stock valued at $5,446,673 in the last 90 days. Corporate insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.